• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Living with dengue: ‘It’s everywhere and there’s nothing we can do about it.’

Home > Stories

Living with dengue: ‘It’s everywhere and there’s nothing we can do about it.’

26 Jan 2022

Dengue is one of the top ten threats to public health worldwide. Dengue incidence has grown by 85% over the last 50 years. It continues to spread rapidly, fuelled by urbanization, population growth and climate change. Today, nearly 4 billion people in 129 countries are at risk of dengue infection.

To hear more about people’s experiences, we visited recovered dengue patients in the historic city of Malacca in Malaysia, living in the highest risk areas for dengue, known as ‘red zones’.

We met 31-year-old Tan Jhii Lian (Jhii), who in 2020 was infected by dengue twice in just three months.

Woman standing in front of a car

The first time, she went to see a doctor with a fever of 40°C (104 °F), body aches, and weakness. When he found out where she lived, he immediately ordered a dengue test. The result was positive.

’I didn’t know what to expect, but I heard it could be quite serious. Because I have worked in hospitals, I have seen cases where dengue patients had to be admitted into the intensive care unit,’ Jhii said. She was sent home with medicines and instructions to rest, but as her fever got worse, Jhii found herself in and out of different hospitals.

Leaving her young baby was the most difficult aspect of the new mother’s ordeal. ‘The first time my daughter was just around six months old, and the worst thing is that she’s never been away from me before since her birth. We were so worried about who would take care of her and how long I would have to be in the ward.‘

‘I was stuck there with a high fever. I was shivering even with a jacket and four layers of blankets covering me. There’s no treatment, there’s only symptomatic treatment available right now. I couldn’t fight back, so I just endured the whole experience.’

Following her recovery, Jhii and her family took stringent preventative precautions. They covered all doors and windows with mosquito netting and avoided going out at peak mosquito biting times. But just three months later, she got infected again.

‘After you  get infected with dengue, you don’t know what will happen. How your body reacts is based on luck and other factors. I got it again three months after the first infection. Who can be so unlucky?’

While the first infection had caused symptoms of high fever, lethargy, and muscle aches, this time she had severe abdominal cramps and diarrhoea. ’The second time, I couldn’t even take in any food or even water. Just one sip made the cramp so bad. It was really painful.’

Because there is no specific treatment for dengue, once again the hospital could only give her supportive care. ‘They gave me anti-diarrhoea medication, paracetamol, and a drip, that’s all.‘

Because of the infections, Jhii told us ‘my milk supply halved after each infection and as a result, I only managed to breastfeed my daughter until she was ten months old.’

City of Malacca, Malaysia

Living in a dengue red zone puts Jhii at high risk. ’I’m still living in fear that I might contract the virus a third and fourth time. Every time they do the fogging, we know that there is a case, and it’s actually quite frequent in my neighbourhood.’

’I know that the more times you get dengue, the more serious it can get. So, of course I’m scared. The first time I just had a fever, but the second time my blood result was worrying. So, I’m scared of what will happen if I get it a third time.’ Jhii also particularly worries about her daughter. ’She’s so young. For me having been infected twice, there’s a very high risk of her getting it. I just can’t imagine a baby contracting dengue.’ 

’Dengue is everywhere and there’s nothing we can do about it. If we had a vaccine or medication to treat it, at least we would know there’s a solution.’

Across the world dengue causes immense individual suffering and puts enormous pressure on over-burdened health systems. In South-East Asia the incidence of dengue increased by 46% between 2015 and 2019, mostly affecting children under the age of 15. Severe dengue is a leading cause of hospitalization and death in many countries. In Malaysia, the last major outbreak in 2019, as an epidemic swept South-East Asia, saw a new record of 131,000 cases.

DNDi is partnering with dengue-endemic countries on a project that aims to find a safe, affordable, and effective treatment for dengue.

READ more about this partnership

Photo credit: Abang Amirrul Hadi – DNDi

Dengue Asia Malaysia

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License